Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibit HIV protease enzyme
|
| gptkbp:appointed_by |
oral medication
|
| gptkbp:approves |
gptkb:1995
gptkb:FDA |
| gptkbp:associated_with |
reduced transmission risk
improved life expectancy |
| gptkbp:availability |
widely available in pharmacies
|
| gptkbp:can_be_used_with |
integrase inhibitors
NNRT Is NRT Is |
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:contraindication |
liver disease
severe allergies |
| gptkbp:developed_by |
pharmaceutical companies
|
| gptkbp:education |
necessary for understanding treatment
|
| gptkbp:example |
gptkb:Atazanavir
gptkb:Lopinavir gptkb:Nelfinavir gptkb:Ritonavir gptkb:Saquinavir |
| gptkbp:formulation |
gptkb:item
tablets capsules |
| gptkbp:future_plans |
patient-centered approaches
improved formulations new drug combinations |
| gptkbp:global_presence |
widely used
|
| gptkbp:historical_significance |
changed HIV treatment landscape
|
| https://www.w3.org/2000/01/rdf-schema#label |
HIV protease inhibitors
|
| gptkbp:impact |
immune system
viral load |
| gptkbp:interacts_with |
certain medications
|
| gptkbp:invention |
patented
generic versions available |
| gptkbp:is_monitored_by |
liver function
blood glucose lipid levels |
| gptkbp:is_used_for |
treatment of HIV/ AIDS
|
| gptkbp:marketed_as |
various brand names
|
| gptkbp:price |
varies by country
|
| gptkbp:provides_information_on |
recommended in treatment guidelines
|
| gptkbp:research_areas |
pharmaceutical companies
biotech companies various universities |
| gptkbp:research_focus |
drug resistance
new formulations long-acting injectables |
| gptkbp:side_effect |
fatigue
headache nausea diarrhea hyperlipidemia can improve quality of life |
| gptkbp:targets |
gptkb:HIV_virus
|
| gptkbp:type_of_care |
important for effectiveness
|
| gptkbp:bfsParent |
gptkb:simvastatin
gptkb:Vytorin gptkb:Lipitor gptkb:apixaban gptkb:atorvastatin |
| gptkbp:bfsLayer |
5
|